MX2023008834A - Biomarcador para evaluar el riesgo de desarrollar covid-19 agudo y covid-19 post-agudo. - Google Patents

Biomarcador para evaluar el riesgo de desarrollar covid-19 agudo y covid-19 post-agudo.

Info

Publication number
MX2023008834A
MX2023008834A MX2023008834A MX2023008834A MX2023008834A MX 2023008834 A MX2023008834 A MX 2023008834A MX 2023008834 A MX2023008834 A MX 2023008834A MX 2023008834 A MX2023008834 A MX 2023008834A MX 2023008834 A MX2023008834 A MX 2023008834A
Authority
MX
Mexico
Prior art keywords
covid
subject
risk
masp
methods
Prior art date
Application number
MX2023008834A
Other languages
English (en)
Inventor
Gregory A Demopulos
Munehisa Yabuki
Thomas Dudler
Nicholas James Lynch
Hans- Wilhelm Schwaeble
Kathleen Shaffer
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2023008834A publication Critical patent/MX2023008834A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se describen composiciones, kits y métodos para determinar la concentración del complejo MASP-2/C1-INH en fase fluida en un fluido biológico, tal como un fluido biológico obtenido de un sujeto infectado con SARS-CoV-2. También se describen métodos para usar dichas composiciones, métodos y kits para la detección del complejo MASP-2/C1-INH para determinar el estado de activación de la vía de las lectinas en un sujeto mamífero y evaluar de ese modo el riesgo de que un sujeto esté o haya sido infectado con SARS-CoV-2 para desarrollar SDRA relacionado con COVID-19 u otro mal resultado, o determinar la necesidad de tratamiento o la eficacia del tratamiento de un sujeto que lo necesita con un inhibidor del complemento tal como un agente inhibidor de MASP-2.
MX2023008834A 2021-02-05 2022-02-04 Biomarcador para evaluar el riesgo de desarrollar covid-19 agudo y covid-19 post-agudo. MX2023008834A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163146479P 2021-02-05 2021-02-05
US202163277361P 2021-11-09 2021-11-09
PCT/US2022/015303 WO2022170090A1 (en) 2021-02-05 2022-02-04 Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19

Publications (1)

Publication Number Publication Date
MX2023008834A true MX2023008834A (es) 2023-09-14

Family

ID=82741911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008834A MX2023008834A (es) 2021-02-05 2022-02-04 Biomarcador para evaluar el riesgo de desarrollar covid-19 agudo y covid-19 post-agudo.

Country Status (9)

Country Link
US (1) US20220308056A1 (es)
EP (1) EP4288098A1 (es)
JP (1) JP2024509702A (es)
KR (1) KR20230138505A (es)
AU (1) AU2022216290A1 (es)
CA (1) CA3206789A1 (es)
IL (1) IL304927A (es)
MX (1) MX2023008834A (es)
WO (1) WO2022170090A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121370A1 (en) * 2022-12-09 2024-06-13 Universität Zürich Complement component 7 as a diagnostic marker and therapeutic target

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN107011443B (zh) * 2011-05-04 2021-04-30 奥默罗斯公司 用于抑制masp-2依赖的补体活化的组合物
EP3116911B8 (en) * 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2019231935A1 (en) * 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
US20200140570A1 (en) * 2018-06-22 2020-05-07 Omeros Corporation Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders

Also Published As

Publication number Publication date
US20220308056A1 (en) 2022-09-29
IL304927A (en) 2023-10-01
AU2022216290A1 (en) 2023-09-14
WO2022170090A1 (en) 2022-08-11
KR20230138505A (ko) 2023-10-05
EP4288098A1 (en) 2023-12-13
JP2024509702A (ja) 2024-03-05
CA3206789A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
EA202192260A1 (ru) Биомаркеры циклин-зависимой киназы 2 и их применение
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX2023008834A (es) Biomarcador para evaluar el riesgo de desarrollar covid-19 agudo y covid-19 post-agudo.
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
JP2016536012A5 (es)
Steubl et al. C-terminal agrin fragment-a new fast biomarker for kidney function in renal transplant recipients
Saadeh et al. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
BR112018005770A2 (pt) comutação dinâmica entre teste de profundidade tardia e teste de profundidade conservativa
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
EA202191354A1 (ru) Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
CA3056911A1 (en) Methods for diagnosing and treating inflammatory bowel disease
Rowbotham et al. Measurement of crosslinked fibrin derivatives in patients undergoing abdominal surgery: use in the diagnosis of postoperative venous thrombosis
MX2023010694A (es) Métodos para predecir la respuesta al tratamiento en la colitis ulcerosa.
Bay et al. Pre-transplant levels of ficolin-3 are associated with kidney graft survival
BR112022009708A2 (pt) Métodos de tratamento de câncer com uso de inibidores dkk-1
PH12018501813A1 (en) Early detection of hepatocellular carcinoma
Günebakmaz et al. Increased serum asymmetric dimethylarginine level is an independent predictor of contrast-induced nephropathy
Taranta‐Janusz et al. Osteopontin and symmetric dimethylarginine plasma levels in solitary functioning kidney in children
BR112022001140A2 (pt) Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose
Zarbock et al. Acute kidney injury in cardiac Surgery
Mallongi et al. Relationships between lead contaminated seafood consumption and blood pressure among fisherman communities at the Makassar Coastal Areas, Indonesia
Grynchuk et al. SCALE FOR PREDICTING THE RISK OF RECURRENT ULCERATIVE BLEEDING
Pérez-Sánchez et al. Nephrotoxicity biomarkers able to identify oncological patients at risk of developing kidney damage